Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC decreased its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 325,036 shares of the life sciences company's stock after selling 46,575 shares during the quarter. Natixis Advisors LLC owned 0.20% of Illumina worth $43,435,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Bleakley Financial Group LLC purchased a new position in Illumina in the 4th quarter worth about $751,000. Zacks Investment Management bought a new stake in shares of Illumina during the 3rd quarter valued at about $2,924,000. Van ECK Associates Corp increased its position in shares of Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of Illumina during the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP increased its position in shares of Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after purchasing an additional 6,263 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Down 0.2 %

Shares of Illumina stock traded down $0.17 during trading on Thursday, hitting $84.79. 1,612,333 shares of the stock traded hands, compared to its average volume of 2,084,730. The firm has a market cap of $13.43 billion, a P/E ratio of -11.04, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52-week low of $80.18 and a 52-week high of $156.66. The stock's fifty day simple moving average is $110.28 and its 200 day simple moving average is $128.89.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ILMN. Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Barclays reissued an "underweight" rating on shares of Illumina in a report on Tuesday, March 11th. Guggenheim reduced their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. Stephens reissued an "overweight" rating and issued a $156.00 target price on shares of Illumina in a report on Tuesday, March 11th. Finally, Royal Bank of Canada reduced their target price on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.